A Randomized, Open-Label, Parallel-Arm Study to Assess the Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab (BIIB037) Compared to a Single, Weight-Based Intravenous Dose in Healthy Volunteers
Latest Information Update: 26 Oct 2021
Price :
$35 *
At a glance
- Drugs Aducanumab (Primary) ; Aducanumab (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Biogen
- 22 Oct 2021 Status changed from recruiting to completed.
- 09 Jul 2021 Status changed from not yet recruiting to recruiting.
- 16 Jun 2021 New trial record